Rick Hodder
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Rick Hodder has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Alan G. Kaplan
2 shared publicationsBrian H. Rowe
2 shared publicationsJ. Mark FitzGerald
2 shared publicationsM. Diane Lougheed
2 shared publicationsR. Andrew McIvor
2 shared publicationsBobbie Lee
Eli Lilly Canada Inc., Eli Lilly Canada Inc., 3650 Danforth Ave, Toronto, ON, Canada, M1N 2E8
1 shared publication
Latest Publications
- Open Access
- 9 November 2009
- Published by CMA Impact Inc. in Canadian Medical Association Journal
- Vol. 182 (3) , 265-272
Management of acute asthma in adults in the emergency department: assisted ventilation
Jordan, a 32-year-old man with chronic, poorly controlled asthma, has been in the emergency department for 1 hour with only partial response to aggressive bronchodilator therapy and a single intravenous dose of corticosteroids. He is considered to be at high risk for potentially fatal asthma because
- 9 November 2009
- Published by CMA Impact Inc. in Canadian Medical Association Journal
- Vol. 182 (3) , 265-272
Open AccessManagement of acute asthma in adults in the emergency department: assisted ventilation
Jordan, a 32-year-old man with chronic, poorly controlled asthma, has been in the emergency department for 1 hour with only partial response to aggressive bronchodilator therapy and a single intravenous dose of corticosteroids. He is considered to be at high risk for potentially fatal asthma because
- 26 October 2009
- Published by CMA Impact Inc. in Canadian Medical Association Journal
- Vol. 182 (2) , E55-E67
Management of acute asthma in adults in the emergency department: nonventilatory management
Acute asthma is a common medical emergency, which, despite repeated review 1–6 and the publication of international 7 and national 8 guidelines, including the Canadian Asthma Consensus Guidelines, 9–11 often remains poorly managed. 12–20 Although there are some signs that evidence-based management of this disorder is improving, 17,21–23 a recent survey of the management of asthma in children and adults in the emergency department revealed wide variations in care and substantial gaps in management in certain key areas. 19 These included poor adherence to published guidelines on the management of asthma, infrequent measurement of peak expiratory flow, infrequent use of systemic corticosteroids and poor rates of referral to asthma educational services.
- 26 October 2009
- Published by CMA Impact Inc. in Canadian Medical Association Journal
- Vol. 182 (2) , E55-E67
Management of acute asthma in adults in the emergency department: nonventilatory management
Acute asthma is a common medical emergency, which, despite repeated review 1–6 and the publication of international 7 and national 8 guidelines, including the Canadian Asthma Consensus Guidelines, 9–11 often remains poorly managed. 12–20 Although there are some signs that evidence-based management of this disorder is improving, 17,21–23 a recent survey of the management of asthma in children and adults in the emergency department revealed wide variations in care and substantial gaps in management in certain key areas. 19 These included poor adherence to published guidelines on the management of asthma, infrequent measurement of peak expiratory flow, infrequent use of systemic corticosteroids and poor rates of referral to asthma educational services.
- Open Access
- 1 October 2009
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. 4, 381-90
Patient preferences for inhaler devices in chronic obstructive pulmonary disease: experience with Respimat® Soft Mist™ Inhaler
Peer reviewed article authored by (Richard Hodder, David Price). Read article or submit your manuscript for publishing.
- 1 October 2009
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. 4, 381-90
Open AccessPatient preferences for inhaler devices in chronic obstructive pulmonary disease: experience with Respimat® Soft Mist™ Inhaler
Peer reviewed article authored by (Richard Hodder, David Price). Read article or submit your manuscript for publishing.
- Open Access
- 20 May 2009
- Published by Springer Nature in Critical Care
- Vol. 13 (3) , R78
Early drotrecogin alpha (activated) administration in severe sepsis is associated with lower mortality: a retrospective analysis of the Canadian ENHANCE cohort
Introduction: Early multimodal treatment of severe sepsis, including the use of drotrecogin alfa (activated) (DrotAA) when indicated, is considered essential for optimum outcome. However, predicting which infected patients will progress to severe sepsis and the need for aggressive intervention continues to be problematic. We therefore wished to explore whether there were any potential early markers that might predict improved survival in response to early use of DrotAA in patients with severe sepsis. In particular, in the dynamic setting of severe sepsis, we postulated that changes in markers reflecting evolving rather than baseline clinical status might guide therapy. Methods: Data on a cohort of 305 Canadian patients from the open label ENHANCE trial of DrotAA in severe sepsis was retrospectively analyzed to search for potential clinical predictors of outcome in severe sepsis. Patients received a 96-hour infusion of DrotAA and were followed for 28 days. The association between time to treatment and mortality within subgroups defined by dynamic changes in various potential markers was explored. Results: Mortality at 28 days was 22.6% and the variables of age, time to treatment, and early changes in serum creatinine and platelet count were identified by logistic regression as independent predictors of mortality. Across all age ranges, 28-day mortality was lower when DrotAA was administered within 24 hours of first sepsis-induced organ dysfunction compared to administration after 24 hours for both subgroups of patients defined by changes in platelet count and creatinine within the first day. Conclusions: These findings suggest that when indicated, treatment with DrotAA should be initiated as soon as possible, regardless of age. Trial Registration: Previous trial registration number: NCT00568893
- 20 May 2009
- Published by Springer Nature in Critical Care
- Vol. 13 (3) , R78
Open AccessEarly drotrecogin alpha (activated) administration in severe sepsis is associated with lower mortality: a retrospective analysis of the Canadian ENHANCE cohort
Introduction: Early multimodal treatment of severe sepsis, including the use of drotrecogin alfa (activated) (DrotAA) when indicated, is considered essential for optimum outcome. However, predicting which infected patients will progress to severe sepsis and the need for aggressive intervention continues to be problematic. We therefore wished to explore whether there were any potential early markers that might predict improved survival in response to early use of DrotAA in patients with severe sepsis. In particular, in the dynamic setting of severe sepsis, we postulated that changes in markers reflecting evolving rather than baseline clinical status might guide therapy. Methods: Data on a cohort of 305 Canadian patients from the open label ENHANCE trial of DrotAA in severe sepsis was retrospectively analyzed to search for potential clinical predictors of outcome in severe sepsis. Patients received a 96-hour infusion of DrotAA and were followed for 28 days. The association between time to treatment and mortality within subgroups defined by dynamic changes in various potential markers was explored. Results: Mortality at 28 days was 22.6% and the variables of age, time to treatment, and early changes in serum creatinine and platelet count were identified by logistic regression as independent predictors of mortality. Across all age ranges, 28-day mortality was lower when DrotAA was administered within 24 hours of first sepsis-induced organ dysfunction compared to administration after 24 hours for both subgroups of patients defined by changes in platelet count and creatinine within the first day. Conclusions: These findings suggest that when indicated, treatment with DrotAA should be initiated as soon as possible, regardless of age. Trial Registration: Previous trial registration number: NCT00568893
- Open Access
- 1 May 2009
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. 4, 225-232
Asthma patients prefer Respimat® Soft Mist™ Inhaler to Turbuhaler®
Peer reviewed article authored by (<p align=
- 1 May 2009
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. 4, 225-232
Open AccessAsthma patients prefer Respimat® Soft Mist™ Inhaler to Turbuhaler®
Peer reviewed article authored by (<p align=
- 1 June 2007
- Vol. 2 (2) , 157-167
Outcomes in COPD patients receiving tiotropium or salmeterol plus treatment with inhaled corticosteroids
Patients with COPD are frequently prescribed inhaled corticosteroids (ICS); however, it is unclear whether the treatment with ICS might modify responses to inhaled bronchodilators. Two 6-month, randomized, placebo-controlled, double-blind, double-dummy, parallel-group studies of tiotropium 18 μg once daily, compared with salmeterol, 50 μg bid, had been conducted in patients with moderate-to-severe COPD. Efficacy was assessed by spirometry, transition dyspnea index (TDI), St. George’s Respiratory Questionnaire (SGRQ), and exacerbations. Data from both studies were combined to form subgroups with regard to concurrent use of ICS. 796 patients receiving ICS were separately analyzed from 390 patients not receiving ICS. Mean age was 64 years, and pre-bronchodilator FEV1 was 1.06 L (ICS group) and 1.13 L (non-ICS group). Both bronchodilators increased morning mean ± SE pre-dose FEV1 compared with placebo (ICS groups: tiotropium 110 ± 20 mL, salmeterol 80 ± 20 mL; non-ICS groups: tiotropium 150 ± 30 mL, salmeterol 110 ± 30 mL; p > 0.05 for tiotropium vs salmeterol). Improvements in TDI and SGRQ and frequency of exacerbations also tended to be more profound for tiotropium. Treatment with tiotropium in patients with moderate-to-severe COPD was superior to salmeterol in lung function, irrespective of concurrent use of ICS.
- 1 June 2007
- Vol. 2 (2) , 157-167
Outcomes in COPD patients receiving tiotropium or salmeterol plus treatment with inhaled corticosteroids
Patients with COPD are frequently prescribed inhaled corticosteroids (ICS); however, it is unclear whether the treatment with ICS might modify responses to inhaled bronchodilators. Two 6-month, randomized, placebo-controlled, double-blind, double-dummy, parallel-group studies of tiotropium 18 μg once daily, compared with salmeterol, 50 μg bid, had been conducted in patients with moderate-to-severe COPD. Efficacy was assessed by spirometry, transition dyspnea index (TDI), St. George’s Respiratory Questionnaire (SGRQ), and exacerbations. Data from both studies were combined to form subgroups with regard to concurrent use of ICS. 796 patients receiving ICS were separately analyzed from 390 patients not receiving ICS. Mean age was 64 years, and pre-bronchodilator FEV1 was 1.06 L (ICS group) and 1.13 L (non-ICS group). Both bronchodilators increased morning mean ± SE pre-dose FEV1 compared with placebo (ICS groups: tiotropium 110 ± 20 mL, salmeterol 80 ± 20 mL; non-ICS groups: tiotropium 150 ± 30 mL, salmeterol 110 ± 30 mL; p > 0.05 for tiotropium vs salmeterol). Improvements in TDI and SGRQ and frequency of exacerbations also tended to be more profound for tiotropium. Treatment with tiotropium in patients with moderate-to-severe COPD was superior to salmeterol in lung function, irrespective of concurrent use of ICS.
- Open Access
- 1 January 2007
- Published by Wiley in Canadian Respiratory Journal
- Vol. 14 (4) , 229-234
The Paradox of Adult Asthma Control: “Who’s in Control Anyway?”
Surveys of Canadian patients with asthma and their physicians consistently report satisfaction with asthma management; however, when objective indicators are used, these same surveys also observe very poor levels of asthma control. The reasons for this apparent discrepancy, with an emphasis on the factors influencing adherence to therapy, are explored in the present review. Clues to the identification of patients at risk of dying from asthma and an approach to difficult asthma are discussed.
- 1 January 2007
- Published by Wiley in Canadian Respiratory Journal
- Vol. 14 (4) , 229-234
Open AccessThe Paradox of Adult Asthma Control: “Who’s in Control Anyway?”
Surveys of Canadian patients with asthma and their physicians consistently report satisfaction with asthma management; however, when objective indicators are used, these same surveys also observe very poor levels of asthma control. The reasons for this apparent discrepancy, with an emphasis on the factors influencing adherence to therapy, are explored in the present review. Clues to the identification of patients at risk of dying from asthma and an approach to difficult asthma are discussed.